



Evolution of Antimicrobial Resistance and Implications for Therapy in Respiratory Infections

Guest Editor:

Dr. Regev Cohen

1. Infectious Diseases and
Infection Control Units, Hillel-
Yaffe Medical Center, Hadera,
Israel
2. The Ruth and Bruce Rappaport
Faculty of Medicine, Technion,
Haifa, Israel

Deadline for manuscript
submissions:

31 July 2024

Message from the Guest Editor

Dear Colleagues,

Respiratory infections in humans, caused by viruses, bacteria and fungi, are amongst the most common burdens on human health, in both the community and healthcare settings. Viral pandemics such as *Influenzae A* (H1N1pdm09) and the recent SARS-CoV-2 have amplified outbreaks of MDR bacterial cross-infections within facilities across the globe. MDR and pan-drug-resistant *Pseudomonas aeruginosa*, Carbapenem-resistant *Acinetobacter baumannii*, carbapenemase-producing Enterobacterales (CPE), MRSA, as well as resistant fungi such as *Candida auris* and *Aspergillus* spp, are now commonly seen and pose great danger to human lives in intensive care units.

This Special Issue of *Antibiotics* invites researchers to submit work on the evolution and development of AMR among respiratory pathogens acquired in the community or in healthcare facilities, the epidemiology of acquired and inherent AMR among respiratory pathogens, as well new diagnostic tools and therapy implications designed to confront it, including the use of existing and new antimicrobial drugs.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)